Abstract: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising MiniVectors™ encoding a nucleic acid sequence and methods of gene therapy using MiniVectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising MiniVectors™ encoding a nucleic acid sequence and methods of gene therapy using MiniVectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy and prophylaxis against infection using minivectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.

Abstract: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.

Abstract: The present invention is directed to a jet nebulizer assembly for administering drugs via aerosols in a patient's home and a method of treating a cancer in a patient's home by utilizing the jet nebulizer assembly.

Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.

Abstract: Disclosed are aqueous aerosol droplets containing liposome or interacted liposome-drug or medication combination particles in a continuous phase of air or oxygen-enriched air advantageous for the treatment of a wide variety of diseases. The drug or medication is interacted with the liposome membrane so that on its rupture the drug or medication is not lost from the liposome. Different methods of preparation of the aerosol particles containing the liposome and interacted liposome-drug combination particles are described which can be used in small particle aerosol treatment. The majority of the aerosol droplets containing the liposome particles alone or with drugs has a diameter less than 5 microns and has an aerodynamic mass median diameter ranging from about 1 to 3 microns, and the liposome and interacted-liposome drug particles are substantially uniform in size and less than 1 micron in diameter.